Beta Bionics (NASDAQ:BBNX) Posts Quarterly Earnings Results, Misses Expectations By $1.40 EPS

Beta Bionics (NASDAQ:BBNX) issued its earnings results on Tuesday. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.42) by ($1.40), Zacks reports. Beta Bionics updated its FY 2025 guidance to EPS.

Beta Bionics Price Performance

BBNX opened at $15.22 on Wednesday. Beta Bionics has a 52 week low of $13.64 and a 52 week high of $24.50.

Insider Buying and Selling

In related news, insider Mike Mensinger bought 33,350 shares of Beta Bionics stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the acquisition, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were bought at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the transaction, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Baird R W upgraded shares of Beta Bionics to a “hold” rating in a research note on Thursday, February 20th. Leerink Partnrs raised Beta Bionics to a “strong-buy” rating in a research note on Monday, February 24th. Robert W. Baird assumed coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a “neutral” rating and a $20.00 target price for the company. Lake Street Capital initiated coverage on shares of Beta Bionics in a research report on Monday, February 24th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Piper Sandler assumed coverage on shares of Beta Bionics in a research note on Monday, February 24th. They issued an “overweight” rating and a $26.00 target price for the company. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Beta Bionics has an average rating of “Moderate Buy” and an average target price of $24.83.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.